News
AstraZeneca (AZN) stock is in focus as its Saphnelo injection for systemic lupus erythematosus succeeds in a Phase 3 trial as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback